Domestic hair loss treatment-related stocks are showing mixed movements during trading on the 2nd. While the KOSPI and KOSDAQ are undergoing corrections due to weakness in U.S. semiconductor stocks and domestic large-cap semiconductor shares, bio and pharmaceutical stocks are exhibiting differentiated patterns on an individual stock basis.

[Gaining Stocks] During the afternoon session, Daewoong Pharmaceutical showed strength, trading at 125,700 won, up 7,400 won (6.26%) from the previous trading day. Antrogen rose by 650 won (3.23%) to 20,800 won, and J2K Bio recorded 8,310 won, up 260 won (3.23%).

[Declining Stocks] Meanwhile, JW Pharmaceutical, cited as a hair loss treatment-related stock, traded at 1,681 won, down 166 won (8.99%), while Hyundai Pharm widened its losses, falling by 420 won (7.50%) to 5,180 won. In addition, Bioneer (-2.79%), Withus Pharmaceutical (-2.96%), and Allico Pharmaceutical (-3.17%) each failed to escape downward trends.

[Market Analysis and Outlook] On this day, profit-taking sell-offs expanded across growth stocks in the domestic stock market as investor sentiment shrank, centering on the semiconductor sector. The pharmaceutical and bio sectors were also affected by this broader market trend, but stock price movements diverged depending on individual companies' research and development (R&D) achievements, product competitiveness, and business outlook.

The industry projects that the hair loss treatment market will continue its steady growth, driven by an aging population and growing interest in beauty and health. Accordingly, new drug development, expansion of functional products, and advancement into overseas markets are cited as key variables that will determine the mid- to long-term competitiveness of related companies.

[※ This is an article written with AI assistance. This article is not an investment recommendation, and the final decision and responsibility for investments lie with the investor.]